Noida, UP -- (SBWire) -- 07/08/2015 --The burden of child pneumonia and diarrhea mortality continues to be most heavily concentrated in just a few countries. The 15 countries with the greatest number of under-five child deaths from pneumonia and diarrhea in 2013 bore 71% of the global burden of child deaths from these two diseases in spite of accounting for only 56% of the world's under five year old population.Improved living standards and access to antibiotics have transformed the trajectory of pneumonia in the developed world.
According to our report, "Global Pneumonia Vaccine Market Outlook 2020", the Pneumonia vaccine market for 2014, which has been estimated at US$ 5.9 Billion is expected to reach US$ 11 Billion by 2020, growing at a CAGR of 11.1% over the six year period. The report offers a clear and succinct take on the current Pneumococcal Vaccine Industry. The regional distribution of the current market has also been discussed.
As vaccines are highly regulated to ensure patients and users have access to safe and effective medicines, the regulatory scenarios for vaccine approval and licensing has also been discussed. It has been noted that individual governments determine which products can be marketed in their countries and many have state-regulated systems governing product pricing.
Lastly, the report talks of the three major players of the industry; GlaxoSmithKline, Pfizer and Merck. The competitive landscape is supplemented with a chapter highlghting the current share of every player in the market. This is followed by company profiles, wherein the general business alongwith the key finanacials of every player have been provided. At the end of every profile, a strength weakness analysis has been performed. The report provides a prudent analysis of the market and is a must have supplement for any player interested in the industry.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM764.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
About RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.
Pneumococcal Vaccine Industry to Grow US$ 11 Billion by 2020
“Ever increasing incidences of chronic respiratory diseases coupled with government support will push the growth of the Pneumonia Vaccine Industry”, says RNCOS.